Streetbeat News

Price Targets

ANSS

Oppenheimer analyst Ken Wong maintains an Outperform rating on Ansys (NASDAQ:ANSS) but has lowered the price target from $400 to $320.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:54 pm

DOCN

Piper Sandler analyst James Fish maintains a Neutral rating on DigitalOcean Holdings (NYSE:DOCN) and raises the price target from $22 to $25.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:52 pm

TFX

JMP Securities analyst David Turkaly maintains a Market Outperform rating on Teleflex (NYSE:TFX) but lowers the price target from $315 to $285.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:51 pm

NET

Piper Sandler analyst James Fish has maintained a Neutral rating on Cloudflare (NYSE:NET) and lowered the price target from $64 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:51 pm

PTGX

JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) and raises the price target from $35 to $37.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:49 pm

PRTA

JMP Securities analyst Jason Butler maintains a Market Outperform rating on Prothena Corp (NASDAQ:PRTA) but lowers the price target from $83 to $81.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:48 pm

PCTY

JMP Securities analyst Patrick Walravens maintains a Market Outperform rating on Paylocity Holding (NASDAQ:PCTY) but lowers the price target from $320 to $250.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:46 pm

LNTH

JMP Securities analyst David Turkaly maintains a Market Outperform rating on Lantheus Holdings (NASDAQ:LNTH) but lowers the price target from $130 to $100.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:44 pm

DVAX

JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on Dynavax Technologies (NASDAQ:DVAX) and raises the price target from $25 to $27.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:43 pm

ACAD

JMP Securities analyst Jason Butler maintains a Market Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raises the price target from $39 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 7:41 pm